PDS Biotech to Present at the LD Micro Main Event XVI
26 sept. 2023 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
25 sept. 2023 08h00 HE
|
PDS Biotechnology Corporation
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a...
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
20 sept. 2023 16h05 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
20 sept. 2023 08h00 HE
|
PDS Biotechnology Corporation
PDS0202 (Infectimune® + COBRA influenza antigens) vaccination also prevented illness/weight loss Vaccine protected against replication of the virus in the lungs of ferrets after challenge with the...
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
13 sept. 2023 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 16h05 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
06 sept. 2023 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
16 août 2023 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
14 août 2023 07h30 HE
|
PDS Biotechnology Corporation
Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023Biomarker data from VERSATILE-002 to be...
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
14 août 2023 07h00 HE
|
PDS Biotechnology Corporation
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in...